IL254424A0 - Disubstituted heterocyclic tricyclic compounds - Google Patents

Disubstituted heterocyclic tricyclic compounds

Info

Publication number
IL254424A0
IL254424A0 IL254424A IL25442417A IL254424A0 IL 254424 A0 IL254424 A0 IL 254424A0 IL 254424 A IL254424 A IL 254424A IL 25442417 A IL25442417 A IL 25442417A IL 254424 A0 IL254424 A0 IL 254424A0
Authority
IL
Israel
Prior art keywords
heterocyclic compounds
tricyclic heterocyclic
substituted tricyclic
substituted
compounds
Prior art date
Application number
IL254424A
Other languages
English (en)
Hebrew (he)
Inventor
Hai-Yun Xiao
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Original Assignee
Bristol Myers Squibb Co
Xiao Hai Yun
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Xiao Hai Yun, T G Murali Dhar, Jingwu Duan, Bin Jiang, Andrew J Tebben filed Critical Bristol Myers Squibb Co
Publication of IL254424A0 publication Critical patent/IL254424A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
IL254424A 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds IL254424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
IL254424A0 true IL254424A0 (en) 2017-11-30

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254424A IL254424A0 (en) 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds

Country Status (14)

Country Link
US (1) US10189840B2 (enExample)
EP (1) EP3271360B1 (enExample)
JP (1) JP6793657B2 (enExample)
KR (1) KR102654709B1 (enExample)
CN (1) CN107635993B (enExample)
AU (1) AU2016233288A1 (enExample)
BR (1) BR112017019773A2 (enExample)
CA (1) CA2980159A1 (enExample)
EA (1) EA032315B1 (enExample)
ES (1) ES2797805T3 (enExample)
IL (1) IL254424A0 (enExample)
MX (1) MX2017011434A (enExample)
SG (1) SG11201707469WA (enExample)
WO (1) WO2016149436A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018167176A1 (en) 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ[1,2−a]ピリジン誘導体
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
KR20100033484A (ko) * 2007-06-26 2010-03-30 사노피-아벤티스 어닐링된 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 금속 촉매된 합성
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8084620B2 (en) * 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
US9512124B2 (en) 2014-10-06 2016-12-06 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf

Also Published As

Publication number Publication date
US20180111936A1 (en) 2018-04-26
MX2017011434A (es) 2018-01-25
AU2016233288A1 (en) 2017-11-09
ES2797805T3 (es) 2020-12-03
KR20170129810A (ko) 2017-11-27
EA201792034A1 (ru) 2018-03-30
CN107635993B (zh) 2020-05-22
CN107635993A (zh) 2018-01-26
JP2018508553A (ja) 2018-03-29
WO2016149436A1 (en) 2016-09-22
CA2980159A1 (en) 2016-09-22
BR112017019773A2 (pt) 2018-05-15
US10189840B2 (en) 2019-01-29
SG11201707469WA (en) 2017-10-30
EP3271360B1 (en) 2020-04-22
EP3271360A1 (en) 2018-01-24
EA032315B1 (ru) 2019-05-31
JP6793657B2 (ja) 2020-12-02
KR102654709B1 (ko) 2024-04-03

Similar Documents

Publication Publication Date Title
ZA201807249B (en) Heterocyclic compound
SG11201605417QA (en) Heterocyclic compounds
SMT202400533T1 (it) Composto eterociclico
IL247018A0 (en) Heterocyclic compound
IL248991A0 (en) Converted dihydroisoquinolinone compounds
IL253361A0 (en) A tricyclic spiro compound
IL285105A (en) Heterocyclic compound
IL254424A0 (en) Disubstituted heterocyclic tricyclic compounds
IL257501B (en) Compounds containing heterocyclic tricyclic compounds
IL262448B (en) Disubstituted heterocyclic bicyclic compounds
HUE049482T2 (hu) Új heterociklusos vegyület
IL254890B (en) The tercyclic compound
IL254320A0 (en) organic compounds
IL249907A0 (en) Tricyclic substances containing a triazole ring
GB201521758D0 (en) Organic compounds
GB201501824D0 (en) Organic compounds
HUP1700522A1 (hu) Triciklusos vegyületek